등온핵산증폭기술 시장 규모, 점유율, 동향 및 예측 : 제품, 기술, 용도, 최종사용자, 지역별(2026-2034년)

The global isothermal nucleic acid amplification technology market size was valued at USD 3.8 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 9.0 Billion by 2034, exhibiting a CAGR of 9.92% during 2026-2034. North America currently dominates the market, holding a market share of over 43.4% in 2025 . The rising demand for fast and accurate diagnostics, increasing prevalence of infectious diseases, rapid advancements in portable testing devices, and expanding applications across healthcare, food safety, and environmental monitoring, with strong support from government initiatives are major factors boosting the isothermal nucleic acid amplification technology market share.

The ongoing development in isothermal nucleic acid amplification technology (INAAT) for detecting coronavirus disease (COVID-19) represents one of the key factors positively influencing the isothermal nucleic acid amplification technology market growth. In line with this, the increasing geriatric population globally and the rising prevalence of cancer and other chronic medical disorders, along with the escalating demand for efficient diagnosis and treatment alternatives, are contributing to the market growth. The population of individuals aged 65 and older is anticipated to double in the next 30 years, reaching 1.6 billion by 2050. Additionally, it was projected that in 2023, the United States would experience 1,958,310 new cancer diagnoses and 609,820 cancer-related deaths. These increased rates have heightened the demand for effective treatment options. Apart from this, the adoption of loop-mediated isothermal amplification (LAMP) tests to amplify deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) and the identification of genetically modified organisms (GMOs) is catalyzing the demand for INAAT.

With increasing domestic and international travel, urbanization, and environmental changes, the United States is facing a growing risk of infectious disease outbreaks. Diseases such as tuberculosis, West Nile virus, and emerging threats like Zika and chikungunya have highlighted the need for efficient and widespread diagnostic tools. For instance, the United States reported 9,633 cases of tuberculosis (TB) disease in the year, which is a 15.6% hike in comparison with 2022. Isothermal nucleic acid amplification technology has become a vital solution for identifying these pathogens rapidly and accurately. This technology's ability to detect even low levels of pathogens without requiring thermal cycling makes it faster and more efficient than traditional methods. U.S. public health organizations, including the Centers for Disease Control and Prevention (CDC), are focusing on isothermal diagnostics to improve their ability to detect and respond to health issues at an earlier stage. For instance, regions with frequent mosquito-borne disease activity are adopting these diagnostic tools to monitor and control outbreaks more effectively.

ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET TRENDS:

Increased Demand for Rapid Diagnostic Solutions

The increasing need for faster, more accurate, and cost-effective diagnostic solutions for infectious diseases and genetic testing will be the impetus for widespread adoption of INAAT globally. In contrast to traditional PCR-based methods, INAAT offers quick results without demanding the use of complex thermal cycling equipment. Hence, INAAT is highly amenable to point-of-care testing in resource-poor settings as well as the management of public health emergencies like the COVID-19 pandemic.

In addition, increased incidence of chronic and life-threatening diseases is creating an added demand for improved diagnostic technologies. For example, a World Health Organization report of February 2022 cited that cancer was responsible for one-fifth of global deaths, showing the urgency in providing timely, accurate diagnostics. INAAT being a reliable process for fast delivery is an invaluable tool for detection at early stages and management of disease, therefore, fueling the isothermal nucleic acid amplification technology market demand.

Advancements in Healthcare and Personalized Medicine

The rising trend of personalized medicine and molecular diagnostics is highly fueling the need for advanced testing technologies like Isothermal Nucleic Acid Amplification Technology (INAAT). INAAT enables the rapid and cost-effective detection of specific genetic mutations, pathogens, or biomarkers, which support more targeted treatments and improved healthcare outcomes. As precision medicine continues to gain momentum, INAAT is playing a critical role in enhancing diagnostic capabilities, ensuring timely interventions, and facilitating customized therapies.

The growing use of molecular diagnostics across different healthcare settings is contributing to the growth of the isothermal nucleic acid amplification technology market. For instance, in December 2021, Hologic, Inc. (US) introduced the Panther Trax system, which provides full automation to accommodate the demands of high-volume testing. This system, commercially available in the US, Europe, Canada, Australia, and New Zealand, reflects the commitment of the healthcare sector toward using advanced technologies for more efficient and accurate diagnostic results. As it is, precision medicine continues to evolve, and INAAT will be the heart of all diagnostics and patient care in the future.

Technological Innovations and Integration with Portable Devices

Recent isothermal amplification techniques, such as Loop-mediated Isothermal Amplification (LAMP) and Helicase-Dependent Amplification (HDA), have enhanced the sensitivity, specificity, and convenience of Isothermal Nucleic Acid Amplification Technology (INAAT). These technological advancements are the key to furthering INAAT's utility in different fields of diagnostics. Furthermore, the advancement of integration of portable, handheld devices with INAAT has widened its applications in field diagnostics, and thus, efficient testing in remote areas, military settings, and travel-related health screenings is hence contributing to the market expansion as a whole.

Further fueling this requirement is the surging global health concerns such as the cancer burden, which continues to increase over time. IARC has documented in its December 2020 report that a total of 19.3 million new cancer cases occurred across the world in 2020. Such prevalence calls for a rapid, efficient, and precise diagnostic method to be in both clinical and field diagnostic environments; thus, the role of INAAT in diagnostics becomes a fundamental one.

ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY INDUSTRY SEGMENTATION:

Analysis by Product:

• Instruments
• Reagents

As per the isothermal nucleic acid amplification technology market forecast, reagents hold the majority of the isothermal nucleic acid amplification technology market share with 62.7%, driven by their critical role in enabling accurate and efficient amplification processes. These include primers, enzymes, nucleotides, and buffers, which are essential for ensuring reliable diagnostic outcomes. The growing demand for point-of-care (POC) testing and rapid diagnostics has fueled the consumption of reagents, as they are vital for tests targeting infectious diseases, genetic disorders, and oncology biomarkers. Additionally, the increased adoption of isothermal technologies in research settings and diagnostic labs has amplified the need for high-quality and customizable reagents tailored to specific applications.

Analysis by Technology:

• Helicase-Dependent Amplification (HDA)
• Nicking Enzyme Amplification Reaction (NEAR)
• Loop-Mediated Isothermal Amplification (LAMP)
• Strand Displacement Amplification (SDA)
• Nucleic Acid Sequence-Based Amplification (NASBA)
• Transcription Mediated Amplification (TMA)
• Single Primer Isothermal Amplification (SPIA)
• Others

Based on the isothermal nucleic acid amplification technology market outlook, transcription mediated amplification (TMA) accounts for the majority of the total market share as it allows a clinical laboratory to perform nucleic acid test (NAT) assays for blood screening with fewer steps and less processing time. Its great sensitivity, quick processing, and direct RNA target amplification are other factors contributing to its expansion. Because TMA yields reliable findings even with low pathogen loads, it is often employed in clinical diagnostics, especially for the detection of infectious illnesses including HIV, hepatitis, and respiratory infections. Compared to conventional processes, it is quicker and more economical since its isothermal nature removes the need for heat cycling. Its market leadership is further supported by the technology's increasing use in molecular diagnostics and its shown dependability in extensive screening programs, particularly for STIs.

Analysis by Application:

• Infectious Disease Diagnosis
  • Hepatitis
  • CT/NG
  • HIV
  • Influenza
  • Others
• Blood Screening

Due to the pressing requirement for quick and precise pathogen identification, infectious disease diagnosis holds a major market share of 35.7%. There is a greater need for this technology for early diagnosis and efficient treatment due to the rising incidence of illnesses including tuberculosis, HIV, hepatitis, and respiratory infections. It has proven invaluable in public health emergencies due to its capacity to provide trustworthy outcomes at point of care settings and environments with limited resources. Supported by investments in diagnostics and government-led efforts to increase healthcare accessibility, this category continues to dominate due to persistent worldwide concerns about new infectious illnesses and the need for improved disease monitoring.

Analysis by End-User:

• Hospitals
• Diagnostic Laboratories
• Research Laboratories

Based on the isothermal nucleic acid amplification technology market trends, hospitals presently dominate the market with 40.0% share, due to their critical role in diagnosing and managing a wide range of diseases. These facilities frequently use the technology for its rapid turnaround time and high accuracy, which are essential for emergency cases, infectious disease management, and preoperative evaluations. Hospitals are also primary points for large-scale disease screening programs and play a significant role in epidemic and pandemic responses. The availability of trained professionals and advanced infrastructure in hospitals further enhances the adoption of these technologies, making them central to modern healthcare diagnostics.

Regional Analysis:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

In 2025, North America exhibits a clear dominance in the market with a share of 43.4%, driven by advanced healthcare infrastructure, strong investment in research and development, and the high prevalence of infectious diseases such as influenza, HIV, and hepatitis. The United States, in particular, leads the region due to its early adoption of innovative diagnostic technologies and significant funding from government bodies like the NIH and CDC to combat public health challenges. The region also benefits from the presence of key market players and a well-established regulatory framework that supports the rapid commercialization of diagnostic solutions. Furthermore, the increasing demand for point-of-care testing and personalized medicine is boosting market growth in North America.

KEY REGIONAL TAKEAWAYS:

UNITED STATES ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET ANALYSIS

The rising prevalence of chronic diseases in the United States is a significant factor driving the expansion of the isothermal nucleic acid amplification technology (INAAT) market. According to the CDC's 2024 report, about 157 million Americans were living with chronic diseases in 2020, and 81 million had multiple conditions. The growing burden of chronic diseases, which often require regular and accurate diagnostic testing, has created a pressing need for efficient and accessible diagnostic technologies. INAAT, offering rapid, cost-effective, and easy-to-use testing without complex thermal cycling equipment, is well-positioned to address this demand. It will be an imperative requirement in early detection and management of chronic diseases that INAAT solutions provide quicker results for genetic mutations, pathogens, and biomarkers. The growth of frequent and accurate testing for the management of disease is on the rise. Combined with the shift toward point-of-care testing, this trend further accelerates the growth of the INAAT solution market. With an increase in chronic conditions prevalent in the United States, INAAT technologies will drive the market with great influence.

EUROPE ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET ANALYSIS

The increasing incidence of cancer within the European Union is a key factor propelling the growth of the isothermal nucleic acid amplification technology (INAAT) market. New cancer cases in the EU have increased by 2.3% from 2020 to 2.74 million in 2022, according to industry reports. As cancer detection and management are becoming increasingly important, there is a growing demand for advanced diagnostic tools that provide quick and accurate results. Improvement in the efficiency and affordability with which INAAT detects specific genetic mutations and biomarkers is the way forward for improved cancer diagnostics. The point-of-care testing device, in that regard, holds a special significance for areas not well-equipped to access high-technology laboratories. The speed with which INAAT can provide correct results without involving complex equipment enhances its value immensely in the case of early diagnosis of cancer-a major determinant of proper treatment. This, again, will accelerate the market's growth as it is going to increase INAAT technology adoption because of a steady rise in Europe's cancer burden.

ASIA PACIFIC ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET ANALYSIS

The rising incidence of breast and cervical cancer in the Asia-Pacific region is a primary driver of growth for the Isothermal Nucleic Acid Amplification Technology (INAAT) market. According to the World Economic Forum's 2023 report, the number of breast cancer cases in the region is expected to increase by 21%, and cervical cancer incidence is projected to increase by 19%. This increased cancer burden requires advanced and rapid diagnostic solutions that can improve early detection and treatment outcomes. With its delivery of accurate, timely results regarding genetic mutations, pathogens, and biomarkers, INAAT becomes increasingly important for cancer diagnostics. The integration of the technology into portable, user-friendly devices adds to its importance in resource-poor areas and the Asia-Pacific region. By enabling faster and cost-effective testing without the necessity of complex laboratory equipment, INAAT is going to help satisfy the increasing need for efficient diagnostic solutions, hence contributing to market growth in the region.

LATIN AMERICA ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET ANALYSIS

The rising cancer burden in Latin America is the main growth driver for the INAAT market. Industry reports indicate that the Asia-Pacific region experiences around 1.5 million new cancer cases and 700,000 cancer-related deaths each year. This trend shows an alarming rate, which emphasizes the need for efficient and rapid diagnostic solutions that may enhance early detection and improve treatment outcomes. INAAT offers tremendous advantages in cancer diagnostics by providing rapid, accurate, and cost-effective testing for genetic mutations, biomarkers, and pathogens. The technology's ability to deliver results quickly without the need for complex thermal cycling equipment makes it highly suitable for point-of-care testing, especially in regions with limited healthcare infrastructure. As the number of cancer cases keeps growing in LAC, INAAT is ready to take up the role that will be supportive of early detection of cancer and personalized medicine to drive the market growth in this region.

MIDDLE EAST AND AFRICA ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET ANALYSIS

According to an industry report, Saudi Arabia recorded 17.4 percent Y-Y growth to 2023 as its significant hike in the outlay towards Research and development reaching SR 22.61 Billion (USD 6.02 Billion), would be another turning point driving in the development across the MEA Isothermal Nucleic Acid Amplification Technology (INAAT) marketplace. As the need for quick and sensitive diagnostics continues to rise, especially for infectious diseases and genetic testing, the ability of INAAT to deliver fast, affordable, and efficient testing without complex thermal cycling equipment is finding favor. This investment is most likely to enhance innovations and infrastructures in health care, therefore promoting INAAT in the region. In addition, Saudi Arabia focuses on enhancing the capabilities of its healthcare system, aligning with broader goals in MEA, namely improving diagnostic accuracy and accessibility. Therefore, INAAT will contribute to the development of the market in the region, which in turn will assist in addressing regional healthcare challenges.

COMPETITIVE LANDSCAPE:

Major players are strengthening their positions by concentrating on innovation, strategic alliances, and regional growth. To satisfy the increasing need for quick and precise diagnosis, businesses are launching sophisticated diagnostic systems with increased sensitivity, mobility, and usability. Numerous businesses are making significant investments in research and development (R&D) to provide next-generation technologies specifically suited for use in genetic testing, cancer, and infectious disease diagnostics. Through strategic collaborations with governments, non-governmental organizations, and healthcare providers, these businesses are extending their reach into developing countries and environments with limited resources. Partnerships to provide low-cost diagnostic services in underprivileged areas, for example, have also accelerated. Additionally, a number of participants are improving data sharing and real-time monitoring by utilizing digital technologies including cloud-based platforms and smartphone connection.

The report provides a comprehensive analysis of the competitive landscape in the isothermal nucleic acid amplification technology market with detailed profiles of all major companies, including:

• Abbott Laboratories
• Eiken Chemical Co. Ltd.
• Genomtec
• Hologic Inc.
• Meridian Bioscience Inc.
• OptiGene Limited
• Qiagen NV
• QuidelOrtho Corporation
• Thermo Fisher Scientific Inc.
• Ustar Biotechnologies

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Isothermal Nucleic Acid Amplification Technology Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of Covid-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Instruments
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Reagents
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Technology

• 7.1 Helicase-Dependent Amplification (HDA)
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Nicking Enzyme Amplification Reaction (NEAR)
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Loop-Mediated Isothermal Amplification (LAMP)
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Strand Displacement Amplification (SDA)
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Nucleic Acid Sequence-Based Amplification (NASBA)
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Transcription Mediated Amplification (TMA)
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast
• 7.7 Single Primer Isothermal Amplification (SPIA)
  • 7.7.1 Market Trends
  • 7.7.2 Market Forecast
• 7.8 Others
  • 7.8.1 Market Trends
  • 7.8.2 Market Forecast

8 Market Breakup by Application

• 8.1 Infectious Disease Diagnosis
  • 8.1.1 Market Trends
  • 8.1.2 Major Types
    • 8.1.2.1 Hepatitis
    • 8.1.2.2 CT/NG
    • 8.1.2.3 HIV
    • 8.1.2.4 Influenza
    • 8.1.2.5 Others
  • 8.1.3 Market Forecast
• 8.2 Blood Screening
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by End-User

• 9.1 Hospitals
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Diagnostic Laboratories
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Research Laboratories
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Others
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Eiken Chemical Co. Ltd.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
  • 14.3.3 Genomtec
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Hologic Inc.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Meridian Bioscience Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 OptiGene Limited
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
  • 14.3.7 Qiagen NV
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 QuidelOrtho Corporation
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Thermo Fisher Scientific Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Ustar Biotechnologies
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio